1657 related articles for article (PubMed ID: 18599183)
1. Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.
Taniguchi Y; Yoshihara S; Hoshida Y; Inoue T; Fujioka T; Ikegame K; Kawakami M; Masuda T; Aozasa K; Kawase I; Ogawa H
Exp Hematol; 2008 Sep; 36(9):1216-25. PubMed ID: 18599183
[TBL] [Abstract][Full Text] [Related]
2. Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.
Pelot MR; Pearson DA; Swenson K; Zhao G; Sachs J; Yang YG; Sykes M
Biol Blood Marrow Transplant; 1999; 5(3):133-43. PubMed ID: 10392959
[TBL] [Abstract][Full Text] [Related]
3. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
Li JM; Gorechlad J; Larsen CP; Waller EK
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
[TBL] [Abstract][Full Text] [Related]
4. Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation.
Yang J; Gao L; Liu Y; Ren Y; Xie R; Fan H; Qian K
Transfusion; 2010 Feb; 50(2):407-17. PubMed ID: 19788510
[TBL] [Abstract][Full Text] [Related]
5. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
Johnson BD; Becker EE; LaBelle JL; Truitt RL
J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
[TBL] [Abstract][Full Text] [Related]
6. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
7. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
8. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
9. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
10. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
11. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
Strober S
Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
[TBL] [Abstract][Full Text] [Related]
12. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
[TBL] [Abstract][Full Text] [Related]
13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
14. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
15. [Role of alloreactive natural killer cell in mouse MHC haploidentical bone marrow transplantation].
He Y; Wang HH; Wang M; Zhou Z; Zhai WJ; Huang Y; Jiang EL; Wang ZD; Zhou SY; Liu QG; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):82-6. PubMed ID: 16732957
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
17. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
18. [Experimental study on NK cells promoting donor marrow engraftment and hematopoietic reconstitution after MHC haploidentical BMT in mice].
Wang CY; Guo KY; Wu BY; Wu LX; Jiang ZY; Pan XH
Zhonghua Xue Ye Xue Za Zhi; 2004 May; 25(5):290-2. PubMed ID: 15182539
[TBL] [Abstract][Full Text] [Related]
19. Anti-NK cell treatment induces stable mixed chimerism in MHC-mismatched, T cell-depleted, nonmyeloablative bone marrow transplantation.
Cho SG; Shuto Y; Soda Y; Nakazaki Y; Izawa K; Uchimaru K; Takahashi S; Tani K; Tojo A; Asano S
Exp Hematol; 2004 Dec; 32(12):1246-54. PubMed ID: 15588949
[TBL] [Abstract][Full Text] [Related]
20. An MHC-compatible allogeneic bone marrow donor with a distinct role of T cell subsets in graft-versus-leukemia effect and lethal graft-versus-host disease.
Aizawa S; Kamisaku H; Sado T
Bone Marrow Transplant; 1995 Oct; 16(4):603-9. PubMed ID: 8528179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]